Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Oct;35(5):495-497.
doi: 10.5114/ada.2018.77241. Epub 2018 Jul 19.

Omalizumab improves forced expiratory volume in 1 second in patients with severe asthma

Krzysztof Pałgan  1 , Magdalena Żbikowska-Götz  1 , Kinga Lis  1 , Elżbieta Chrzaniecka  1 , Zbigniew Bartuzi  1
Affiliations

Omalizumab improves forced expiratory volume in 1 second in patients with severe asthma

Krzysztof Pałgan et al. Postepy Dermatol Alergol. 2018 Oct.

Abstract

Introduction: Asthma is a multiphenotypic disease, and therapeutic managenment in patients with severe asthma is particulary difficult, with conventional treatment of severe asthma showing poor efficacy.

Aim: To analyse forced expiratory volume in 1 s (FEV1) following the adminstration of omalizumab.

Material and methods: Six patinents (mean age: 50 ±12.6) with severe, uncontrolled asthma according to the GINA guidelines were enrolled in the study.

Results: Treatment with omalizumab increased in all subjects FEV1 by 17.28 ±13.4% after months and 18.57 ±13.4% after 12 months of treatment.

Conclusions: These results provides further evidence that therapy with omalizumab improves spiromtric parameters in severe asthma.

Keywords: asthma; forced expiratory volume in 1 s; omalizumab; spirometry.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Total IgE levels in patients prior to omalizumab enrolment
Figure 2
Figure 2
Effects of omalizumab therapy on FEV1
Figure 3
Figure 3
Increase in FEV1 in patients treated with omalizumab
See this image and copyright information in PMC

References

    1. Global Initiative for Asthma (GINA) National Heart, Lung and Blood Institute (NHLBI) Global strategy for asthma management and prevention Bethesda (MD): Global Initiative for Asthma (GINA), National Heart, Lung and Blood Institute (NHLBI) 2006. Available from: www.ginasthma.com.
    1. Raoufy MR, Ghafari T, Darooei R, et al. Classification of asthma based on nonlinear analysis of breathing pattern. PLoS One. 2016;11:e0147976. - PMC - PubMed
    1. Busse W, Corren J, Lanier BQ, et al. Omalizumab, antiIgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108:184–90. - PubMed
    1. Kupryś-Lipińska I, Majak P, Molinska J, Kuna P. Effectiveness of the Polish program for the treatment of severe allergic asthma with omalizumab: a single-center experience. BMC Pulm Med. 2016;16:61. - PMC - PubMed
    1. Lai T, Wang S, Xu Z, et al. Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis. Sci Rep. 2015;5:8191. - PMC - PubMed